JP2001520677A - 皮膚の光老化を抑制するための組成物および方法 - Google Patents
皮膚の光老化を抑制するための組成物および方法Info
- Publication number
- JP2001520677A JP2001520677A JP50283399A JP50283399A JP2001520677A JP 2001520677 A JP2001520677 A JP 2001520677A JP 50283399 A JP50283399 A JP 50283399A JP 50283399 A JP50283399 A JP 50283399A JP 2001520677 A JP2001520677 A JP 2001520677A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- composition
- uva
- exposure
- mmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 108
- 238000000034 method Methods 0.000 title claims abstract description 62
- 206010051246 Photodermatosis Diseases 0.000 title claims abstract description 39
- 230000008845 photoaging Effects 0.000 title claims abstract description 37
- 230000002401 inhibitory effect Effects 0.000 title claims description 22
- 206010015150 Erythema Diseases 0.000 claims abstract description 103
- 231100000321 erythema Toxicity 0.000 claims abstract description 88
- 230000005855 radiation Effects 0.000 claims abstract description 78
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 32
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 30
- 150000004492 retinoid derivatives Chemical class 0.000 claims abstract description 30
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 29
- 229940124761 MMP inhibitor Drugs 0.000 claims abstract description 20
- 230000001404 mediated effect Effects 0.000 claims abstract description 20
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 16
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 16
- 239000011718 vitamin C Substances 0.000 claims abstract description 16
- -1 2-furyldioxime Chemical compound 0.000 claims abstract description 10
- 239000004098 Tetracycline Substances 0.000 claims abstract description 6
- 230000004060 metabolic process Effects 0.000 claims abstract description 6
- 229960002180 tetracycline Drugs 0.000 claims abstract description 6
- 235000019364 tetracycline Nutrition 0.000 claims abstract description 6
- 229930101283 tetracycline Natural products 0.000 claims abstract description 6
- 150000003522 tetracyclines Chemical class 0.000 claims abstract description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 88
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 88
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 49
- 229960001727 tretinoin Drugs 0.000 claims description 45
- 229930002330 retinoic acid Natural products 0.000 claims description 44
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 23
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 20
- 239000002981 blocking agent Substances 0.000 claims description 19
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 17
- 229960001679 octinoxate Drugs 0.000 claims description 16
- 230000006698 induction Effects 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical group OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims description 11
- 229960001173 oxybenzone Drugs 0.000 claims description 11
- 229960003471 retinol Drugs 0.000 claims description 11
- 235000020944 retinol Nutrition 0.000 claims description 11
- 239000011607 retinol Substances 0.000 claims description 11
- 229930003427 Vitamin E Natural products 0.000 claims description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 10
- 235000019165 vitamin E Nutrition 0.000 claims description 10
- 229940046009 vitamin E Drugs 0.000 claims description 10
- 239000011709 vitamin E Substances 0.000 claims description 10
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 9
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 9
- 230000000903 blocking effect Effects 0.000 claims description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- 230000001976 improved effect Effects 0.000 claims description 4
- 150000003852 triazoles Chemical class 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 claims 1
- 108010021724 tonin Proteins 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 87
- 206010042496 Sunburn Diseases 0.000 abstract description 11
- 101150053185 P450 gene Proteins 0.000 abstract description 3
- 150000003851 azoles Chemical class 0.000 abstract description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 1
- 229960004125 ketoconazole Drugs 0.000 abstract 1
- 102000029816 Collagenase Human genes 0.000 description 45
- 108060005980 Collagenase Proteins 0.000 description 45
- 229960002424 collagenase Drugs 0.000 description 43
- 239000003981 vehicle Substances 0.000 description 27
- 230000008832 photodamage Effects 0.000 description 26
- 239000000516 sunscreening agent Substances 0.000 description 23
- 230000000475 sunscreen effect Effects 0.000 description 19
- 102000013382 Gelatinases Human genes 0.000 description 18
- 108010026132 Gelatinases Proteins 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- 230000000699 topical effect Effects 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 16
- 229960003987 melatonin Drugs 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 14
- 229960001138 acetylsalicylic acid Drugs 0.000 description 14
- RBOZTFPIXJBLPK-HWAYABPNSA-N (NE)-N-[(2E)-1,2-bis(furan-2-yl)-2-hydroxyiminoethylidene]hydroxylamine Chemical compound O\N=C(/C(=N\O)/C1=CC=CO1)\C1=CC=CO1 RBOZTFPIXJBLPK-HWAYABPNSA-N 0.000 description 13
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 13
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 102100023132 Transcription factor Jun Human genes 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000004224 protection Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 8
- 230000037338 UVA radiation Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 235000006539 genistein Nutrition 0.000 description 5
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 5
- 229940045109 genistein Drugs 0.000 description 5
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 5
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 5
- 235000008696 isoflavones Nutrition 0.000 description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 5
- 235000005875 quercetin Nutrition 0.000 description 5
- 229960001285 quercetin Drugs 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 150000002515 isoflavone derivatives Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- QUAMTGJKVDWJEQ-UHFFFAOYSA-N octabenzone Chemical group OC1=CC(OCCCCCCCC)=CC=C1C(=O)C1=CC=CC=C1 QUAMTGJKVDWJEQ-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000012211 Retinoic Acid 4-Hydroxylase Human genes 0.000 description 3
- 108010022037 Retinoic Acid 4-Hydroxylase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Chemical compound O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- 101000642333 Homo sapiens Survival of motor neuron-related-splicing factor 30 Proteins 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 206010033372 Pain and discomfort Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 2
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 2
- 102100036412 Survival of motor neuron-related-splicing factor 30 Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- KGUMXGDKXYTTEY-FRCNGJHJSA-N all-trans-4-hydroxyretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(O)CCC1(C)C KGUMXGDKXYTTEY-FRCNGJHJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000341 effect on erythema Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- YBGZDTIWKVFICR-UHFFFAOYSA-N octinoxate Chemical compound CCCCC(CC)COC(=O)C=CC1=CC=C(OC)C=C1 YBGZDTIWKVFICR-UHFFFAOYSA-N 0.000 description 2
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 2
- 229960000601 octocrylene Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000037204 skin physiology Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 230000008354 tissue degradation Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000007768 Cellular Retinol-Binding Proteins Human genes 0.000 description 1
- 108010021988 Cellular Retinol-Binding Proteins Proteins 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 101100439669 Drosophila melanogaster chrb gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- HMFDVPSBWOHOAP-YUMQZZPRSA-N Glutathione ethyl ester Chemical compound OC(=O)CNC(=O)[C@H](CSCC)NC(=O)CC[C@H](N)C(O)=O HMFDVPSBWOHOAP-YUMQZZPRSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical class NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010030545 N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide Proteins 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241001518143 Polypodium <fern> Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- 102100021688 Rho guanine nucleotide exchange factor 5 Human genes 0.000 description 1
- 108700024319 S-ethyl glutathione Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 101710149792 Triosephosphate isomerase, chloroplastic Proteins 0.000 description 1
- 101710195516 Triosephosphate isomerase, glycosomal Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 230000003366 colagenolytic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 150000004891 diazines Chemical class 0.000 description 1
- 229960004960 dioxybenzone Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 238000007804 gelatin zymography Methods 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- JUHLGADRXLMTCF-UHFFFAOYSA-N hexyl 3-(4-methoxyphenyl)prop-2-enoate Chemical compound CCCCCCOC(=O)C=CC1=CC=C(OC)C=C1 JUHLGADRXLMTCF-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 238000003674 kinase activity assay Methods 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 108091010987 retinoic acid binding proteins Proteins 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229940065287 selenium compound Drugs 0.000 description 1
- 150000003343 selenium compounds Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 230000005919 time-dependent effect Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Application Of Or Painting With Fluid Materials (AREA)
- Surface Treatment Of Optical Elements (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Laminated Bodies (AREA)
- Paints Or Removers (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. ヒトの皮膚の光老化を抑制するための組成物であって、UVA遮断剤と、 UVB遮断剤と、MMP阻害剤との組み合わせを、局所的に許容可能な担体中に 含む組成物。 2. ヒトの皮膚の光老化を抑制するための方法であって、請求項1に記載の組 成物を毎日皮膚に塗布することを含む方法。 3. 前記MMP阻害剤がレチノイドである、請求項1に記載の組成物。 4. N−アセチルシステインと、FDOと、ビタミンCと、これらの混合物と からなる群から選択される化合物をさらに含む、請求項1に記載の組成物。 5. 前記UVA遮断剤が、4−t−ブチル−4’−メトキシジベンゾイルメタ ンまたはその誘導体である、請求項1に記載の組成物。 6. 前記UVB遮断剤が、オキシベンゾンまたはメトキシシンナメートである 、請求項1に記載の組成物。 7. ローション、クリーム、軟膏、水ベースの液体、油ベースの液体またはス プレー可能な液体として組成されている、請求項1に記載の組成物。 8. 前記レチノイドがレチノイン酸またはレチノールである、請求項3に記載 の組成物。 9. 前記組成物が、テトラサイクリンおよびその誘導体と、皮膚科学的に許容 可能なトリアゾールおよびその誘導体と、レチノイン酸のシトクロムP450媒 介代謝を抑制する化合物と、これらの相溶混合物と、からなる群から選択される 少なくとも1種の化合物をさらに含む、請求項1に記載の組成物。 10. ヒトの皮膚においてUV誘発MMP形成の誘発を抑制することによって ヒトの皮膚の光老化を抑制するための方法であって、NAC、FDO、ビタミン Cまたはこれらの混合物からなる群から選択されるMMP阻害剤と、UVA遮断 剤と、UVB遮断剤との組み合わせを、局所的に許容可能な担体中に含む組成物 を、UV曝露の少なくとも8時間前に前記皮膚に塗布することを含む方法。 11. 前記組成物をUV放射への曝露の少なくとも16時間前に塗布する、請 求項10に記載の方法。 12. 前記UVA遮断剤が、4−t−ブチル−4’−メトキシジベンゾイルメ タンまたはその誘導体である、請求項10に記載の方法。 13. 前記UVB遮断剤が、オキシベンゾンまたはメトキシシンナメートであ る、請求項10に記載の方法。 14. 前記組成物がレチノイドをさらに含む、請求項10に記載の方法。 15. 前記組成物が、テトラサイクリンおよびその誘導体と、皮膚科学的に許 容可能なトリアゾールおよびその誘導体と、レチノイン酸のシトクロムP450 媒介代謝を抑制する化合物と、これらの相溶混合物と、からなる群から選択され る少なくとも1種の化合物をさらに含む、請求項14に記載の方法。 16. 透明または半透明の窓構造体であって、UVA遮断剤およびUVB遮断 剤のコーティングが施されているかまたはこれらが内部に分散されている、改良 された窓構造体。 17. 窓構造体を有する、人間を輸送するための車両または他の装置であって 、請求項16に記載の窓構造体を含む、改良された車両または装置。 18. MED未満のUVによってヒトの皮膚にMMPが誘発されるのを抑制す るための組成物であって、レチノイドと、N−アセチルシステインと、2−フリ ルジオキシム、ビタミンCと、これらの混合物と、からなる群から選択される少 なくとも1種の化合物を、皮膚科学的に許容可能なキャリア中に有効量で含む、 組成物。 19. UVA遮断剤およびUVB遮断剤をさらに含む、請求項18に記載の組 成物。 20. 前記UVA遮断剤が、4−t−ブチル−4’−メトキシジベンゾイルメ タンまたはその誘導体である、請求項19に記載の組成物。 21. 前記UVB遮断剤が、オキシベンゾンまたはメトキシシンナメートであ る、請求項19に記載の組成物。 22. 前記組成物がレチノイドを含み、該レチノイドが、レチノール、レチノ イン酸またはこれらの混合物である、請求項19に記載の組成物。 23. MED未満のUVによってヒトの皮膚にMMPが誘発されるのを抑制す るための方法であって、レチノイドと、N−アセチルシステインと、グルタチオ ンと、2−フリルジオキシムと、ビタミンCと、これらの混合物と、からなる群 から選択される少なくとも1種の成分を有効量で提供し、前記少なくとも1種の 成分を、皮膚科学的に許容可能なキャリア中に組成し、この製剤を皮膚に塗布す ることを含む方法。 24. UVA遮断剤およびUVB遮断剤を提供することをさらに含む、請求項 23に記載の方法。 25. 前記UVA遮断剤が、4−t−ブチル−4’−メトキシジベンゾイルメ タンまたはその誘導体であり、前記UVB遮断剤が、オキシベンゾンまたはメト キシシンナメートである、請求項24に記載の方法。 26. 製剤を少なくとも1日1回皮膚に塗布する、請求項23に記載の方法。 27. UV放射への曝露前に製剤を塗布する、請求項23に記載の方法。 28. 前記製剤が、ローション、クリーム、軟膏、水ベースの液体または油ベ ースの液体である、請求項23に記載の方法。 29. 製剤がスプレー可能なものである、請求項23に記載の方法。 30. 紫外線放射によるヒトの皮膚の間接的な光老化を抑制するための方法で あって、レチノイドを有効量で含む皮膚科学的に許容可能な製剤を提供し、紫外 線放射源に直接または間接的に、日常的かつ規則的に曝露される皮膚に、前記製 剤を少なくとも毎日塗布することを含む方法。 31. 前記レチノイドが、レチノールまたはレチノイン酸である、請求項29 に記載の方法。 32. ヒトの皮膚におけるUV媒介紅斑を抑制するための方法であって、メラ トニン、ビタミンE、ビタミンC、アセチルサリチル酸、2−フリルジオキシム またはこれらの混合物からなる群から選択される少なくとも1種の成分を含む皮 膚科学的に許容可能な組成物を提供し、UV放射への曝露前に前記組成物をヒト の皮膚に塗布することを含む方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4852097P | 1997-06-04 | 1997-06-04 | |
US60/048,520 | 1997-06-04 | ||
US5797697P | 1997-09-05 | 1997-09-05 | |
US60/057,976 | 1997-09-05 | ||
PCT/US1998/011453 WO1998055075A2 (en) | 1997-06-04 | 1998-06-03 | Compositions and methods for inhibiting photoaging of skin |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002071908A Division JP2003034137A (ja) | 1997-06-04 | 2002-03-15 | 皮膚の光老化を抑制するための方法および装置 |
JP2004087496A Division JP2004217670A (ja) | 1997-06-04 | 2004-03-24 | 皮膚の光老化を抑制するための方法および装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001520677A true JP2001520677A (ja) | 2001-10-30 |
JP3554339B2 JP3554339B2 (ja) | 2004-08-18 |
Family
ID=26726211
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50283399A Expired - Fee Related JP3554339B2 (ja) | 1997-06-04 | 1998-06-03 | 皮膚の光老化を抑制するための組成物および方法 |
JP2002071908A Pending JP2003034137A (ja) | 1997-06-04 | 2002-03-15 | 皮膚の光老化を抑制するための方法および装置 |
JP2004087496A Pending JP2004217670A (ja) | 1997-06-04 | 2004-03-24 | 皮膚の光老化を抑制するための方法および装置 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002071908A Pending JP2003034137A (ja) | 1997-06-04 | 2002-03-15 | 皮膚の光老化を抑制するための方法および装置 |
JP2004087496A Pending JP2004217670A (ja) | 1997-06-04 | 2004-03-24 | 皮膚の光老化を抑制するための方法および装置 |
Country Status (21)
Country | Link |
---|---|
US (3) | US6130254A (ja) |
EP (1) | EP0998251A4 (ja) |
JP (3) | JP3554339B2 (ja) |
KR (1) | KR20010013415A (ja) |
CN (1) | CN1259040A (ja) |
AR (1) | AR014877A1 (ja) |
AU (1) | AU8057398A (ja) |
BR (1) | BR9809969A (ja) |
CA (2) | CA2292600C (ja) |
CO (1) | CO4940361A1 (ja) |
EA (1) | EA199901115A1 (ja) |
HN (1) | HN1999000158A (ja) |
ID (1) | ID20400A (ja) |
IL (2) | IL133194A0 (ja) |
MA (1) | MA24560A1 (ja) |
NO (1) | NO995768L (ja) |
NZ (2) | NZ513045A (ja) |
PL (1) | PL337531A1 (ja) |
TN (1) | TNSN98077A1 (ja) |
TW (1) | TWI234467B (ja) |
WO (1) | WO1998055075A2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002080338A (ja) * | 2000-06-20 | 2002-03-19 | Shiseido Co Ltd | 老化防止用皮膚外用剤 |
WO2003063179A1 (fr) * | 2002-01-23 | 2003-07-31 | Allmighty Co., Ltd. | Protection contre les rayonnements et utilisation associee |
JP2004504276A (ja) * | 2000-06-26 | 2004-02-12 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | ヒトの皮膚の光老化を防止するためのegf−rタンパク質チロシンキナーゼ抑制剤の使用 |
JP2006508058A (ja) * | 2002-09-23 | 2006-03-09 | ノボジェン・リサーチ・プロプライエタリー・リミテッド | 皮膚光老化および光線性損傷の治療 |
JP2009545604A (ja) * | 2006-07-31 | 2009-12-24 | イーエルシー マネージメント エルエルシー | ミツガシワ(Menyanthestrifoliata)の葉抽出物を含む老化防止組成物とその使用方法 |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100360121C (zh) | 1997-02-25 | 2008-01-09 | 密执安州立大学董事会 | 防护和处理人皮肤经时性衰老的方法和组合物 |
AUPP112497A0 (en) * | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
CN101332157B (zh) * | 1998-10-09 | 2012-01-11 | 味之素株式会社 | 半胱氨酸衍生物 |
US20060212025A1 (en) | 1998-11-30 | 2006-09-21 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US6283956B1 (en) | 1998-11-30 | 2001-09-04 | David H. McDaniels | Reduction, elimination, or stimulation of hair growth |
US6887260B1 (en) | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US7268148B2 (en) * | 1999-05-20 | 2007-09-11 | Regents Of The University Of Michigan | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
US20040235950A1 (en) * | 1999-05-20 | 2004-11-25 | Voorhees John J. | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
IN2000KO00299A (ja) * | 1999-05-28 | 2005-11-18 | Johnson & Johnson Consumer | |
US20030003170A1 (en) * | 2000-06-02 | 2003-01-02 | Theresa Callaghan | Method for the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium) |
GB9919079D0 (en) * | 1999-08-12 | 1999-10-13 | Clayton Paul R | Skin care product |
FR2805158B1 (fr) * | 2000-02-18 | 2004-12-03 | L M D | Composition cosmetique ou medicamenteuse contenant une lactone sesquiterpenique ou un analogue pour traiter les desordres lies a la croissance pilaire, et son procede de preparation. |
DE10020447A1 (de) * | 2000-03-31 | 2001-10-11 | Henkel Kgaa | Verwendung von Protease-Inhibitoren in der Kosmetik und Pharmazie |
EP1267813A2 (de) * | 2000-03-31 | 2003-01-02 | Henkel Kommanditgesellschaft auf Aktien | Verwendung von protease-inhibitoren in der kosmetik und pharmazie |
AU7311501A (en) | 2000-06-29 | 2002-03-22 | Quick Med Technologies Inc | Cosmetic composition and method |
US20040185127A1 (en) * | 2001-06-29 | 2004-09-23 | Lerner David S. | Cosmetic composition and method |
CA2413660A1 (en) * | 2000-07-06 | 2002-01-17 | The Regents Of The University Of Michigan | Uva (>360-400) and uvb (300-325) specific sunscreens |
FR2811561B1 (fr) * | 2000-07-13 | 2003-03-21 | Oreal | Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase |
EP1191024A1 (en) * | 2000-09-22 | 2002-03-27 | Harald Tschesche | Thiadiazines and their use as inhibitors of metalloproteinases |
FR2815252B1 (fr) * | 2000-10-17 | 2002-12-20 | Oreal | Composition, notamment cosmetique, renfermant du retinol et un compose capable de filtrer le rayonnement uva |
FR2815859B1 (fr) * | 2000-10-26 | 2003-02-28 | Oreal | Utilisation de l'association d'au moins un carotenoide a activite provitaminique a et d'au moins un carotenoide sans activite provitaminique a pour traiter les signes du vieillissement |
FR2815861B1 (fr) * | 2000-10-26 | 2003-02-28 | Oreal | Utilisation de l'association d'au moins un carotenoide et d'au moins un isoflavonoide pour traiter les signes cutanes du vieillissement |
US20020119107A1 (en) * | 2000-12-18 | 2002-08-29 | James Varani | Method for protecting and restoring skin using selective MMP inhibitors |
US20020143059A1 (en) * | 2000-12-28 | 2002-10-03 | Sreekumar Pillai | Skin care product containing retinoids, retinoid booster and phytoestrogens in a dual compartment package |
US20030077343A1 (en) * | 2001-03-16 | 2003-04-24 | Martin Katharine M. | Composition containing feverfew extract and use thereof |
EP1367993B1 (en) * | 2001-03-16 | 2007-05-16 | Johnson & Johnson Consumer Companies, Inc. | Use of a feverfew extract for regulating skin ageing factors |
AU2002311903A1 (en) * | 2001-05-09 | 2002-11-18 | University Hospitals Of Cleveland | Evaluation of ultraviolet radiation damage to skin using new genemarkers, methods and compositions related thereto |
CA2347562A1 (en) * | 2001-05-14 | 2002-11-14 | John Lovaghy | Device for aligning papers flowing in a stream |
FR2826266B1 (fr) * | 2001-06-26 | 2005-02-25 | Oreal | Composition cosmetique ou dermatologique comprenant une association entre un compose de la famille des n-acylaminoamides et au moins un inhibiteur de metalloproteinases matricielles |
US6830746B2 (en) | 2001-09-21 | 2004-12-14 | Playtex Products, Inc. | Sunscreen compositions |
WO2004043469A1 (en) * | 2001-11-16 | 2004-05-27 | Klysz Beatrice M | Anti-aging skin care composition and uses thereof |
KR100432449B1 (ko) * | 2001-11-30 | 2004-05-22 | 우원홍 | 케토코나졸 함유 피부 미백용 외용제 조성물 |
US7799827B2 (en) | 2002-03-08 | 2010-09-21 | Eisai Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
DE10214257A1 (de) * | 2002-03-28 | 2003-10-16 | Merck Patent Gmbh | Verwendung von kompatiblen Soluten zur Inhibierung der Freisetzung von Ceramiden |
US7108860B2 (en) * | 2002-06-06 | 2006-09-19 | Playtex Products, Inc. | Sunscreen compositions |
JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
JP2006522660A (ja) | 2003-04-10 | 2006-10-05 | ライト バイオサイエンス,エルエルシー | 細胞増殖及び遺伝子発現を調節するためのフォトモジュレーション方法及び装置 |
US20050149150A1 (en) * | 2003-07-31 | 2005-07-07 | Light Bioscience L.L.C. | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
FR2861293B1 (fr) * | 2003-10-22 | 2008-10-17 | Greenpharma Sas | Composition pour prevenir ou traiter des affections resultant d'un processus de mort cellulaire comprenant une lactone sesquiterpenique |
EP1591105B1 (de) | 2004-03-17 | 2020-05-27 | Stada Arzneimittel Ag | Verwendung von Antioxidantien zur Herstellung einer pharmazeutischen oder kosmetischen Zusammensetzung zum Schutz der Haut gegen Schädigung durch Infrarot-Strahlung |
ES2534603T3 (es) * | 2004-06-30 | 2015-04-24 | E-L Management Corp. | Composiciones cosméticas y procedimientos que comprenden Rhodiola Rosea |
US20090137556A1 (en) | 2004-08-18 | 2009-05-28 | Ace Aps | Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists |
JP4777738B2 (ja) * | 2004-10-14 | 2011-09-21 | 株式会社 資生堂 | Adam活性阻害物質によるしわの防止または改善 |
US20060265030A1 (en) * | 2004-11-12 | 2006-11-23 | Light Bioscience, Llc | System and method for photodynamic cell therapy |
JP4546228B2 (ja) * | 2004-12-02 | 2010-09-15 | 株式会社資生堂 | 経皮吸収促進用油性皮膚外用組成物 |
US20060286046A1 (en) * | 2005-01-05 | 2006-12-21 | Haber C Andrew | Skin care compositions |
FR2885804A1 (fr) * | 2005-05-17 | 2006-11-24 | Engelhard Corp | Compositions de soins pour la peau, produits les contenant et procedes les utilisant |
US20060292094A1 (en) * | 2005-06-24 | 2006-12-28 | Robert Bell | Composition and method of protection against UV irradiation |
WO2007041230A2 (en) * | 2005-09-30 | 2007-04-12 | Omp, Inc. | Stable ascorbic acid compositions |
ATE511839T1 (de) * | 2005-10-20 | 2011-06-15 | Epipharm Gmbh | Behandlung und prävention von gutartigen pigmentmalen (naevi) mit artemisinin und seinen derivaten |
US20070269534A1 (en) * | 2006-02-02 | 2007-11-22 | Ramirez Jose E | Methods of treating skin to enhance therapeutic treatment thereof |
US20070178058A1 (en) * | 2006-02-02 | 2007-08-02 | Ramirez Jose E | Methods of using stable ascorbic acid compositions |
US20080014156A1 (en) * | 2006-07-12 | 2008-01-17 | Horn Gregory T | Photoprotectant composition for preventing sunburn and sun damage to the skin |
WO2008036979A2 (en) * | 2006-09-22 | 2008-03-27 | Guilford F Timothy | Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes |
EP2337544A2 (en) * | 2007-04-30 | 2011-06-29 | Living Proof, Inc. | Use of matrix metalloproteinase inhibitors in skin care |
FR2924334B1 (fr) * | 2007-11-30 | 2016-03-25 | Lvmh Rech | Composition cosmetique comprenant l'acide 2-glucoside ascorbique et l'ergothioneine. |
WO2009121168A1 (en) * | 2008-04-01 | 2009-10-08 | Biopharmacopae Design International Inc. | Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection |
BRPI0924172B1 (pt) * | 2009-01-05 | 2024-02-20 | Ernest T. Armstrong | Protetor solar promotor de vitamina d |
US8080265B2 (en) * | 2009-02-20 | 2011-12-20 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating signs of skin aging |
US20110150798A1 (en) * | 2009-12-21 | 2011-06-23 | Sarah Bacus | Compositions and methods for increasing cellular far and bleaching skin |
US20110150856A1 (en) | 2009-12-21 | 2011-06-23 | Sarah Bacus | Compositions and methods for treatment of vitiligo |
US8435541B2 (en) | 2010-09-02 | 2013-05-07 | Bath & Body Works Brand Management, Inc. | Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities |
JP4927206B2 (ja) * | 2010-09-17 | 2012-05-09 | 株式会社ファンケル | コラーゲン産生促進剤、ヒアルロン酸産生促進剤、しわ改善剤 |
JP2012056951A (ja) * | 2011-09-30 | 2012-03-22 | Maruzen Pharmaceut Co Ltd | 皮膚化粧料並びに飲食品 |
ES2378028B1 (es) * | 2012-02-22 | 2013-02-18 | Ignacio Umbert Millet | Composición cosmética para el rejuvenecimiento de la piel y procedimiento y usos correspondientes |
EP2852383A4 (en) * | 2012-05-21 | 2016-03-16 | Dcb Usa Llc | METHODS OF DRUG TEST USING THE ZEBRAFIC MODEL AND COMPOUNDS TESTED THEREIN |
CA3177929A1 (en) | 2012-12-21 | 2014-06-26 | Astellas Institute For Regenerative Medicine | Methods for production of platelets from pluripotent stem cells and compositions thereof |
US9138393B2 (en) | 2013-02-08 | 2015-09-22 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin |
US9144538B2 (en) | 2013-02-08 | 2015-09-29 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin |
JP5768113B2 (ja) * | 2013-11-29 | 2015-08-26 | ポーラ化成工業株式会社 | 前処置用の皮膚外用剤の製造方法 |
US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
KR20160118550A (ko) | 2015-04-02 | 2016-10-12 | 계명대학교 산학협력단 | 초석잠 추출물을 유효성분으로 함유하는 광조사에 의한 피부 세포손상 예방 또는 치료용 약학조성물 |
US11137347B2 (en) | 2015-10-20 | 2021-10-05 | Courage + Khazaka Electronic Gmbh | Optically ascertaining the sun protection factor of sunscreens or other radiation protection agents |
JP2017210442A (ja) * | 2016-05-26 | 2017-11-30 | イノレックス インベストメント コーポレイション | マトリックスメタロプロテイナーゼを阻害して皮膚の老化を軽減する方法及び関連の相乗的組成物 |
KR101882736B1 (ko) * | 2017-07-10 | 2018-07-27 | 김삼 | 멜라토닌, 비타민 c 및 피크노제놀을 유효 성분으로 함유한 피부보호용 조성물 |
US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
JP2018168177A (ja) * | 2018-07-03 | 2018-11-01 | イノレックス インベストメント コーポレイション | マトリックスメタロプロテイナーゼを阻害して皮膚の老化を軽減する方法及び関連の相乗的組成物 |
WO2020115102A1 (en) * | 2018-12-05 | 2020-06-11 | Repoceuticals Aps | Compositions for use in the treatment of photosensitivity |
US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4877805A (en) | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
JPS58181041A (ja) * | 1982-04-16 | 1983-10-22 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
FR2528420A1 (fr) * | 1982-06-15 | 1983-12-16 | Oreal | Nouveaux 3-benzylidene camphres, leur procede de preparation et leur utilisation pour la protection contre les rayons uv |
LU85556A1 (fr) * | 1984-09-26 | 1986-04-03 | Cird | Nouveaux derives de l'acide retinoique,leur procede de preparation et compositions medicamenteuse et cosmetique les contenant |
US4885282A (en) * | 1987-07-02 | 1989-12-05 | Thornfeldt Carl R | Treatment of hyperhidrosis, ichthyosis and wrinkling |
US5260059A (en) * | 1989-04-14 | 1993-11-09 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University | Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor |
US5002760A (en) * | 1989-10-02 | 1991-03-26 | Katzev Phillip K | Retinol skin care composition |
ES2199214T3 (es) * | 1990-04-26 | 2004-02-16 | THE PROCTER & GAMBLE COMPANY | Composiciones quelantes que comprenden compuestos oxima. |
US5073372A (en) * | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
GB9109733D0 (en) | 1991-05-07 | 1991-06-26 | Unilever Plc | Cosmetic composition |
US5296500A (en) | 1991-08-30 | 1994-03-22 | The Procter & Gamble Company | Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy |
EP0614353A1 (en) * | 1991-11-25 | 1994-09-14 | Richardson-Vicks, Inc. | Compositions for regulating skin wrinkles and/or skin atrophy |
US5629365A (en) * | 1992-06-23 | 1997-05-13 | Monsanto Company | UV-absorbing polymer latex |
AU4673993A (en) * | 1992-07-28 | 1994-02-14 | Procter & Gamble Company, The | Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether |
DE4305788C2 (de) * | 1993-02-25 | 1997-06-12 | Beiersdorf Ag | Kosmetische und dermatologische Formulierungen zum Schutze der Haut gegen Oxidationsprozesse |
GB9223235D0 (en) | 1992-11-05 | 1992-12-16 | Unilever Plc | Cosmetic composition |
US5612215A (en) * | 1992-12-07 | 1997-03-18 | Ribozyme Pharmaceuticals, Inc. | Stromelysin targeted ribozymes |
DE4242876C2 (de) * | 1992-12-18 | 1997-11-27 | Beiersdorf Ag | Kosmetische und/oder dermatologische Zubereitungen zur kosmetischen und/oder dermatologischen Pflege der Haut und/oder der Hautanhangsgebilde |
US5459332A (en) * | 1994-03-31 | 1995-10-17 | The United States Of America As Represented By The Secretary Of The Navy | Semiconductor photodetector device |
EP0754039A4 (en) | 1994-04-08 | 2002-07-17 | Procter & Gamble | METHODS OF USING IRON-CONTAINING CHELATES TO REDUCE MAMMALIAN FREE RADICAL DAMAGES |
US6080393A (en) * | 1994-07-09 | 2000-06-27 | Johnson & Johnson Consumer Products, Inc. | Skin care composition comprising a retinoid |
US5618522A (en) * | 1995-01-20 | 1997-04-08 | The Procter & Gamble Company | Emulsion compositions |
US6153176A (en) * | 1995-01-20 | 2000-11-28 | The Procter & Gamble Company | Low pH sunscreen compositions |
WO1996023490A1 (en) * | 1995-02-03 | 1996-08-08 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US5609854A (en) * | 1995-06-06 | 1997-03-11 | Elizabeth Arden Company, Division Of Conopco, Inc. | Thickened and stabilized cosmetic emulsion compositions |
CN1202807C (zh) * | 1995-06-08 | 2005-05-25 | 庄臣消费者有限公司 | 防晒剂组合物 |
US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
US5824702A (en) * | 1996-06-07 | 1998-10-20 | Mount Sinai School Of Medicine Of The City University Of New York | Genistein as a preventive against ultraviolet induced skin photodamage and cancer |
US5916910A (en) * | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
-
1998
- 1998-05-26 TW TW087108160A patent/TWI234467B/zh not_active IP Right Cessation
- 1998-06-02 CO CO98030959A patent/CO4940361A1/es unknown
- 1998-06-03 AR ARP980102601A patent/AR014877A1/es unknown
- 1998-06-03 KR KR19997011416A patent/KR20010013415A/ko not_active Application Discontinuation
- 1998-06-03 IL IL13319498A patent/IL133194A0/xx unknown
- 1998-06-03 CA CA002292600A patent/CA2292600C/en not_active Expired - Fee Related
- 1998-06-03 CN CN98805763A patent/CN1259040A/zh active Pending
- 1998-06-03 WO PCT/US1998/011453 patent/WO1998055075A2/en not_active Application Discontinuation
- 1998-06-03 NZ NZ513045A patent/NZ513045A/xx not_active IP Right Cessation
- 1998-06-03 EA EA199901115A patent/EA199901115A1/ru unknown
- 1998-06-03 US US09/089,914 patent/US6130254A/en not_active Expired - Lifetime
- 1998-06-03 PL PL98337531A patent/PL337531A1/xx unknown
- 1998-06-03 TN TNTNSN98077A patent/TNSN98077A1/fr unknown
- 1998-06-03 EP EP98928879A patent/EP0998251A4/en not_active Ceased
- 1998-06-03 AU AU80573/98A patent/AU8057398A/en not_active Abandoned
- 1998-06-03 JP JP50283399A patent/JP3554339B2/ja not_active Expired - Fee Related
- 1998-06-03 BR BR9809969-8A patent/BR9809969A/pt not_active IP Right Cessation
- 1998-06-03 NZ NZ501634A patent/NZ501634A/en not_active IP Right Cessation
- 1998-06-03 CA CA2601462A patent/CA2601462C/en not_active Expired - Fee Related
- 1998-06-03 MA MA25097A patent/MA24560A1/fr unknown
- 1998-06-04 ID IDP980822A patent/ID20400A/id unknown
-
1999
- 1999-09-10 HN HN1999000158A patent/HN1999000158A/es unknown
- 1999-11-25 NO NO995768A patent/NO995768L/no not_active Application Discontinuation
- 1999-11-29 IL IL133194A patent/IL133194A/en not_active IP Right Cessation
-
2000
- 2000-07-13 US US09/615,218 patent/US6365630B1/en not_active Expired - Lifetime
-
2002
- 2002-03-15 JP JP2002071908A patent/JP2003034137A/ja active Pending
- 2002-04-02 US US10/114,651 patent/US6942870B2/en not_active Expired - Lifetime
-
2004
- 2004-03-24 JP JP2004087496A patent/JP2004217670A/ja active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002080338A (ja) * | 2000-06-20 | 2002-03-19 | Shiseido Co Ltd | 老化防止用皮膚外用剤 |
JP2004504276A (ja) * | 2000-06-26 | 2004-02-12 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | ヒトの皮膚の光老化を防止するためのegf−rタンパク質チロシンキナーゼ抑制剤の使用 |
WO2003063179A1 (fr) * | 2002-01-23 | 2003-07-31 | Allmighty Co., Ltd. | Protection contre les rayonnements et utilisation associee |
JP2006508058A (ja) * | 2002-09-23 | 2006-03-09 | ノボジェン・リサーチ・プロプライエタリー・リミテッド | 皮膚光老化および光線性損傷の治療 |
JP2009545604A (ja) * | 2006-07-31 | 2009-12-24 | イーエルシー マネージメント エルエルシー | ミツガシワ(Menyanthestrifoliata)の葉抽出物を含む老化防止組成物とその使用方法 |
Also Published As
Publication number | Publication date |
---|---|
TNSN98077A1 (fr) | 2005-03-15 |
ID20400A (id) | 1998-12-10 |
NZ513045A (en) | 2002-10-25 |
CA2292600C (en) | 2007-11-27 |
US6365630B1 (en) | 2002-04-02 |
EA199901115A1 (ru) | 2000-06-26 |
WO1998055075A3 (en) | 1999-06-17 |
NZ501634A (en) | 2001-09-28 |
KR20010013415A (ko) | 2001-02-26 |
CO4940361A1 (es) | 2000-07-24 |
JP3554339B2 (ja) | 2004-08-18 |
IL133194A (en) | 2009-05-04 |
CA2601462A1 (en) | 1998-12-10 |
EP0998251A4 (en) | 2000-08-30 |
AR014877A1 (es) | 2001-04-11 |
MA24560A1 (fr) | 1998-12-31 |
AU8057398A (en) | 1998-12-21 |
CN1259040A (zh) | 2000-07-05 |
PL337531A1 (en) | 2000-08-28 |
HN1999000158A (es) | 2001-03-06 |
US6942870B2 (en) | 2005-09-13 |
BR9809969A (pt) | 2000-10-17 |
IL133194A0 (en) | 2001-03-19 |
NO995768L (no) | 2000-01-17 |
JP2003034137A (ja) | 2003-02-04 |
NO995768D0 (no) | 1999-11-25 |
WO1998055075A2 (en) | 1998-12-10 |
TWI234467B (en) | 2005-06-21 |
US6130254A (en) | 2000-10-10 |
US20020106339A1 (en) | 2002-08-08 |
CA2601462C (en) | 2011-03-15 |
EP0998251A2 (en) | 2000-05-10 |
JP2004217670A (ja) | 2004-08-05 |
CA2292600A1 (en) | 1998-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001520677A (ja) | 皮膚の光老化を抑制するための組成物および方法 | |
Lin et al. | Ferulic acid stabilizes a solution of vitamins C and E and doubles its photoprotection of skin | |
McCullough et al. | Prevention and treatment of skin aging | |
ES2475516T3 (es) | Utilización de 5,7-dihidroxi-2-metil-cromen-4-ona para el cuidado de la piel | |
US5837224A (en) | Method of inhibiting photoaging of skin | |
Edlich et al. | Photoprotection by sunscreens with topical antioxidants and systemic antioxidants to reduce sun exposure | |
Hassan et al. | Sunscreens and antioxidants as photo-protective Measures: An update | |
US20050058709A1 (en) | Methods for inhibiting photoaging of human skin using orally-administered agent | |
US20120065261A1 (en) | Creatine compositions for skin treatment | |
Lehmann | Photodermatoses | |
JP2001097888A (ja) | 外用組成物 | |
Bens | Sunscreens | |
Schaefer et al. | State of the art sunscreens for prevention of photodermatoses | |
AU3637499A (en) | Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin | |
AU2002301116B2 (en) | Compositions and Methods for Inhibiting Photoaging of Skin | |
Pathak et al. | Topical and systemic approaches to protection of human skin against harmful effects of solar radiation | |
MXPA99011052A (en) | Compositions and methods for inhibiting photoaging of skin | |
KR100352687B1 (ko) | 광노화를예방하기위한화장품 | |
Godic | SKIN PHOTOAGING AND THE ROLE OF ANTIOXIDANTS IN ITS PREVENTION | |
Miraglia et al. | P & R Scientific | |
FACTOR | COSMETIC DERMATOLOGY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040324 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040507 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090514 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090514 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100514 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110514 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110514 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120514 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120514 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130514 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140514 Year of fee payment: 10 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |